UBS Maintains Neutral on Alignment Healthcare, Raises Price Target to $12
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Kevin Caliendo maintains a Neutral rating on Alignment Healthcare (NASDAQ:ALHC) and raises the price target from $9 to $12.
October 30, 2024 | 1:32 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
UBS has maintained a Neutral rating on Alignment Healthcare but increased the price target from $9 to $12, indicating a more positive outlook.
The increase in price target from $9 to $12 suggests a more optimistic view on Alignment Healthcare's future performance, which could positively influence investor sentiment and potentially lead to a short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100